Acotiamide
From Wikipedia, the free encyclopedia
 |
This article relies largely or entirely upon a single source. (August 2014) |
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
N-{2-[Bis(1-methylethyl)amino]ethyl}-2-{[(2-hydroxy-4,5-dimethoxyphenyl)carbonyl]amino}-1,3-thiazole-4-carboxamide
|
|
| Clinical data | |
| Routes of administration |
Oral |
| Legal status |
|
| Identifiers | |
| CAS Number | 185106-16-5  |
| ATC code | None |
| PubChem | CID 5282338 |
| ChemSpider | 4445505  |
| UNII | D42OWK5383 |
| ChEMBL | CHEMBL2107723 |
| Chemical data | |
| Formula | C21H30N4O5S |
| Molar mass | 450.55 g/mol |
|
|
|
|
| (what is this?) (verify) |
Acotiamide (YM-443, Z-338) is a drug approved in Japan for the treatment of postprandial fullness, upper abdominal bloating, and early satiation due to functional dyspepsia.[1] It acts as an acetylcholinesterase inhibitor.
References[edit]
- ^ Matsueda K, Hongo M, Tack J, Aoki H, Saito Y, Kato H (January 2010). "Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage". Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society 22 (6): 618–e173. doi:10.1111/j.1365-2982.2009.01449.x. PMID 20059698.
|
 |
This article about an amine is a stub. You can help Wikipedia by expanding it. |
 |
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
